Mar 28, 2023 / 03:30PM GMT
Paul Matteis - Stifel Financial Corp. - Analyst
Great. Thanks very much, everybody, for continuing on here. It's my pleasure to be moderating a chat with the CEO of uniQure, Matt Kapusta. We'll probably talk most of the time about Huntington's, but maybe I can just turn it over to Matt briefly to give us a brief update on the AMT-130 study, cadence of readouts, as well as any other quick hits in the pipeline.
So, Matt, thank you again and looking forward to the discussion.
Matt Kapusta - uniQure N.V. - CEO
Yes, Paul, thank you very much for having us here in Stifel. We really appreciate being involved in the conference. So with respect to AMT-130, just to step back, we have our two active clinical trials that are currently ongoing. One is taking place in the United States as a Phase 1/2 and the other one is taking place in Europe as a Phase 1b/2.
They're both exploring two different doses, the same two different doses. And really the only difference is that the US study is a randomized, controlled, double-blinded study with a one-year blinding
Uniqure NV at Stifel CNS Days (Virtual) Transcript
Mar 28, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers